Bumetanide
Bumetanide, Bumex (bumetanide) is a small molecule pharmaceutical. Bumetanide was first approved as Bumex on 1983-02-28. It is used to treat ascites, chronic kidney failure, edema, heart failure, and hypertension amongst others in the USA. The pharmaceutical is active against solute carrier family 12 member 1. In addition, it is known to target G-protein coupled receptor 35 and solute carrier family 12 member 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
Bumetanide, Bumex (discontinued: Bumetanide, Bumex)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Bumetanide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BUMEX | Validus Pharmaceuticals | N-018225 RX | 1983-02-28 | 3 products, RLD |
Show 1 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| bumetanide | ANDA | 2025-09-25 |
| bumex | New Drug Application | 2025-09-08 |
| enbumyst | New Drug Application | 2025-09-24 |
Indications
FDA
EMA
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
C: Cardiovascular system drugs
— C03: Diuretics
— C03C: High-ceiling diuretics
— C03CA: Sulfonamides, high-ceiling diuretics, plain
— C03CA02: Bumetanide
— C03CB: Sulfonamides and potassium in combination, high-ceiling diruetics, excluding thiazides
— C03CB02: Bumetanide and potassium
— C03E: Diuretics and potassium-sparing agents in combination
— C03EB: High-ceiling diuretics and potassium-sparing agents
— C03EB02: Bumetanide and potassium-sparing agents
HCPCS
Code | Description |
|---|---|
| S0171 | Injection, bumetanide, 0.5 mg |
Clinical
Clinical Trials
47 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | EFO_0003144 | I50 | 4 | 2 | 4 | 8 | 4 | 21 |
| Chronic renal insufficiency | D051436 | — | N18 | — | 1 | — | 2 | 2 | 5 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | 2 | 3 |
| Edema | D004487 | — | R60.9 | — | — | 1 | 2 | — | 3 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | — | — | 1 | 1 | 2 |
| Water intoxication | D014869 | — | — | — | 1 | — | 1 | — | 2 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | — | — | — | 1 | — | 1 |
| Cardio-renal syndrome | D059347 | — | — | — | — | — | 1 | — | 1 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | — | — | 1 | — | 1 |
| Iron overload | D019190 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Autism spectrum disorder | D000067877 | — | F84.0 | — | 2 | 2 | — | — | 4 |
| Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | 1 | 2 | — | — | 3 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | 1 | — | — | 1 |
| Congenital heart defects | D006330 | — | Q24.9 | — | 1 | 1 | — | — | 1 |
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | 1 | — | — | 1 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | — | — | 1 |
| Fibrosis | D005355 | — | — | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Brain hypoxia-ischemia | D020925 | EFO_1000846 | P91.6 | 2 | 1 | — | — | — | 2 |
| Seizures | D012640 | — | G40.4 | 2 | 1 | — | — | — | 2 |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | 1 | 1 | — | — | — | 2 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | — | 1 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 1 | — | — | — | 1 |
| Hypokalemic periodic paralysis | D020514 | — | G72.3 | — | 1 | — | — | — | 1 |
| Down syndrome | D004314 | EFO_0001064 | Q90 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 1 | — | — | — | — | 1 |
| Intracranial hemorrhages | D020300 | EFO_0000551 | I62 | 1 | — | — | — | — | 1 |
| Central nervous system diseases | D002493 | — | G96.9 | 1 | — | — | — | — | 1 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | 1 | — | — | — | — | 1 |
| Drug resistant epilepsy | D000069279 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Covid-19 | D000086382 | — | U07.1 | — | — | — | — | 1 | 1 |
| Critical illness | D016638 | — | — | — | — | — | — | 1 | 1 |
| Critical care | D003422 | — | — | — | — | — | — | 1 | 1 |
| Fluid shifts | D018495 | — | — | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Bumetanide |
| INN | bumetanide |
| Description | Bumetanide is a member of the class of benzoic acids that is 4-phenoxybenzoic acid in which the hydrogens ortho to the phenoxy group are substituted by butylamino and sulfamoyl groups. Bumetanide is a diuretic, and is used for treatment of oedema associated with congestive heart failure, hepatic and renal disease. It has a role as a diuretic and an EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor. It is a sulfonamide, an amino acid and a member of benzoic acids. |
| Classification | Small molecule |
| Drug class | diuretics (piretanide type) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 28395-03-1 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1072 |
| ChEBI ID | 3213 |
| PubChem CID | 2471 |
| DrugBank | DB00887 |
| UNII ID | 0Y2S3XUQ5H (ChemIDplus, GSRS) |
Target
Agency Approved
SLC12A1
SLC12A1
Organism
Homo sapiens
Gene name
SLC12A1
Gene synonyms
NKCC2
NCBI Gene ID
Protein name
solute carrier family 12 member 1
Protein synonyms
bumetanide-sensitive cotransporter type 1, Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2, Kidney-specific Na-K-Cl symporter, Na-K-2Cl cotransporter, Na-K-2Cl cotransporter 2, solute carrier family 12 (sodium/potassium/chloride transporter), member 1, solute carrier family 12 (sodium/potassium/chloride transporters), member 1
Uniprot ID
Mouse ortholog
Slc12a1 (20495)
solute carrier family 12 member 1 (Q9Z1E0)
Alternate
SLC12A2
SLC12A2
Organism
Homo sapiens
Gene name
SLC12A2
Gene synonyms
NKCC1
NCBI Gene ID
Protein name
solute carrier family 12 member 2
Protein synonyms
Basolateral Na-K-Cl symporter, bumetanide-sensitive cotransporter type 2, bumetanide-sensitive sodium-(potassium)-chloride cotransporter 1, Bumetanide-sensitive sodium-(potassium)-chloride cotransporter 2, protein phosphatase 1, regulatory subunit 141, solute carrier family 12 (sodium/potassium/chloride transporter), member 2, solute carrier family 12 (sodium/potassium/chloride transporters), member 2
Uniprot ID
Mouse ortholog
Slc12a2 (20496)
solute carrier family 12 member 2 (P55012)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Bumetanide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,359 documents
View more details
Safety
Black-box Warning
Black-box warning for: Bumetanide, Bumex
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,041 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use